Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $101,000.

  • Relay Therapeutics' Gains from Investment Securities was N/A to $12.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.4 million, marking a year-over-year change of. This contributed to the annual value of $101,000 for FY2024, which is 99.18% down from last year.
  • As of FY2024, Relay Therapeutics' Gains from Investment Securities stood at $101,000, which was down 99.18% from $12.4 million recorded in FY2023.
  • Relay Therapeutics' Gains from Investment Securities' 5-year high stood at $46.6 million during FY2022, with a 5-year trough of $101,000 in FY2024.
  • Its 3-year average for Gains from Investment Securities is $19.7 million, with a median of $12.4 million in 2023.
  • In the last 5 years, Relay Therapeutics' Gains from Investment Securities surged by 575.12% in 2022 and then plummeted by 99.18% in 2024.
  • Relay Therapeutics' Gains from Investment Securities (Yearly) stood at $7.7 million in 2020, then decreased by 10.27% to $6.9 million in 2021, then skyrocketed by 575.12% to $46.6 million in 2022, then slumped by 73.42% to $12.4 million in 2023, then slumped by 99.18% to $101,000 in 2024.